Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xeritinib
- Development stage
- Phase 1
- Lead developer
- HUTCHMED
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Xeritinib (also known as HMPL-005) is an orally bioavailable, potent, and highly selective small molecule inhibitor of the Epidermal Growth Factor Receptor (EGFR) tyrosine kinase. Developed by HUTCHMED (formerly Hutchison Whampoa Pharmaceuticals), xeritinib was designed to target tumors characterized by EGFR overexpression or gene amplification. The drug entered Phase 1 clinical development in China, where it was evaluated in patients with advanced malignant solid tumors, including specific cohorts for esophageal cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer (NSCLC). A primary focus of its development was EGFR-amplified esophageal cancer, a population with significant unmet medical need. While it demonstrated a favorable safety profile and target engagement in early studies, xeritinib is no longer listed in the developer's active clinical pipeline as of 2024.
- Other names
- 希瑞替尼
02
Targets
Beyond the preview
Go deeper on xeritinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xeritinib.